How Will the Market React to Revolution Medicines Inc (RVMD) Stock Getting a Bearish Rating

Revolution Medicines Inc (RVMD) stock has fallen 1.45% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Revolution Medicines Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on RVMD!

See Full RVMD Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With RVMD Stock Today?

Revolution Medicines Inc (RVMD) stock is trading at $30.67 as of 11:43 AM on Wednesday, Mar 27, an increase of $0.67, or 2.22% from the previous closing price of $30.00. The stock has traded between $30.02 and $30.67 so far today. Volume today is less active than usual. So far 158,242 shares have traded compared to average volume of 1,675,647 shares. To screen for more stocks like Revolution Medicines Inc click here.

More About Revolution Medicines Inc

Revolution Medicines Inc is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit elusive, frontier targets within notorious growth and survival pathways, with particular emphasis on the RAS and mTOR signaling pathways. The company's products include RMC-4630, a SHP2 inhibitor, RAS(ON) portfolio, and SOS1 and 4EBP1/mTORC1 programs. Click Here to get the full Stock Report for Revolution Medicines Inc stock.